In vivo animal data report on antibiotic resistance extended until mid-Q4 2019

Booking.com

Scandion Oncology A/S (“Scandion Oncology”) today announces that the report on the in vivo animal data on antibiotic resistance SOM-001 is extended until mid-Q4 2019 due to shortage in slots at the provider. This will not affect the company’s goal of finding an overall strategy for commercializing SOM-001 in 2020.
Earlier this year Scandion Oncology announced that a number of its compounds are able to overcome antibiotic resistance in bacterial infections through a different mechanism of action than the one related to reversing resistance to anti-cancer drugs in cancer cells. As previously

Source: In vivo animal data report on antibiotic resistance extended until mid-Q4 2019

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.